United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rixathon) 900mg/500ml in sodium chloride 0.9% infusion bags (special order - rituximab - infusion - 1.8mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

truxima) 900mg/500ml in sodium chloride 0.9% infusion bags (special order - rituximab - infusion - 1.8mg/1ml

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - solution for injection - rituximab 1400 mg / 11.7 ml - rituximab - mabthera subcutaneous formulation is indicated in adults for non-hodgkin`s lymphoma (nhl):• mabthera is indicated for the treatment of previously untreated patients with stage iii-iv follicular lymphoma in combination with chemotherapy.• mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.• mabthera is indicated for the treatment of patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

amring farma s.r.l, romania - rituximab - solution for infussion - 10

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

amring farma s.r.l, romania - rituximab - solution for infussion - 500/50 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: sucrose; water for injections; histidine; polysorbate 80; histidine hydrochloride monohydrate; disodium edetate - non-hodgkin?s lymphoma,ruxience is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia,ruxience is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis,ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy.,ruxience has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),ruxience in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with ruxience have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: histidine; water for injections; disodium edetate; polysorbate 80; histidine hydrochloride monohydrate; sucrose - non-hodgkin?s lymphoma,ruxience is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia,ruxience is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis,ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy.,ruxience has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),ruxience in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with ruxience have not been established.

Uganda - English - National Drug Authority

amring farma s.r.l - rituximab amring - parenteral ordinary vials - 100 mg/10 ml

Uganda - English - National Drug Authority

amring farma s.r.l - rituximab - parenteral ordinary vials - 500 mg/50 ml

Kenya - English - Pharmacy and Poisons Board

rituximab - injection - rituximab 100mg (10mg/ml) - rituximab